Build meaningful biological evidence.
Generate 3D spatial multimodal evidence from human tissues and patient-derived models, alongside therapy studies scoped to specific research questions.
Human biology. In context.
Spatial intelligence
for biology.
Biology in 3D. Understood through time.
OncoVisio combines human tissue research, 3D spatial biology and molecular insight to investigate treatment response. We are developing AI models to connect this evidence and advance therapeutic discovery.
Explore our visionAI-generated concept illustration
Not experimental data
Explore the biology
Tissue / Biology in context
Cells, neighbors and the structures between them.
AI-generated concept illustrations, not experimental imaging. Motion is illustrative; views are not a tracked zoom through one specimen.
01 / Our vision
Making living biology
understandable.
We combine 3D spatial biology, 4D imaging—three dimensions observed through time—and molecular insight to investigate how cells and tissues respond to treatment.
Build intelligence that learns from it.
Develop AI models that connect biological structure, molecular context and change through time—helping scientists ask and test better questions about disease and treatment.
Our AI models are in development. They are not validated tools for clinical prediction or individual treatment decisions.
02 / Our difference
Human tissue.
An integrated perspective.
Our strength is the combination: clinically relevant biology, connected spatial evidence and a team that brings experimental science, therapeutic discovery and AI together.
The biology that matters.
We focus on clinically important questions and unmet treatment needs, using human tissue and patient-derived models to study biology in context.
A more connected view.
We bring 3D structure, observations through time and spatial molecular evidence together to investigate where therapies reach and how cells and tissues respond.
From evidence to insight.
Tissue engineering, proteomics, chemistry, computational biology and AI inform one another—connecting what we can measure to the questions that matter for discovery.
03 / Our capabilities
Better evidence.
Better-informed discovery.
We welcome pharmaceutical, biotechnology, AI and research collaborators to shape focused programs around important biological questions.
Therapy evaluation
in human tissue
Investigate how therapies distribute, interact with cells and influence response in living tissue and patient-derived models, using 3D imaging through time and complementary molecular evidence.
Research may include monoclonal antibodies, ADCs, CAR-T therapies and T-cell engagers, depending on the study.Target & biomarker
research
Connect spatial biology with molecular and clinical context to prioritize target and biomarker hypotheses for further testing.
Biological interpretation grounded in therapeutic discovery experience.Spatial biology
collaborations
Generate and interpret 3D spatial multimodal evidence from collected patient tissues and experimental models to address disease biology and treatment-associated change.
Integrated biological evidence for research and AI development.Studies are scoped collaboratively. Specimen availability, measurable signals, resolution and deliverables depend on the research question and validated assays. Molecular measurements do not imply continuous molecular tracking.
04 / Our team
The disciplines
to bring it together.
Experience in human tissue systems, pharmaceutical discovery and applied AI. A shared purpose: making biological complexity useful for discovery.
Tae Hyun Hwang, PhD
Co-founder & Chief AI OfficerVanderbilt professor. Leads OncoVisio’s AI-for-biology scientific direction, connecting spatial biology and computational research.
Deok-Ho Kim, PhD
Co-founder & Chief Scientific AdvisorJohns Hopkins professor and founder of Curi Bio. Expertise in human tissue models and organ-on-chip systems.
Jinfeng Liu, PhD
Chief Scientific OfficerLeads computational biology, clinical bioinformatics, and target and biomarker research. Former Gilead executive director, with prior Genentech experience.
Kyungdoc Kim, PhD
Chief Technology OfficerLeads AI at Kakao Healthcare; previously led AI-driven digital pathology at VUNO. Leads OncoVisio’s AI engineering and technology development.
Hanjo Lim, PhD
Vice President of OperationsLeads proteomics and chemistry development, with LC/MS expertise. Former Critical Reagent Operation Lead and Principal Scientist at Genentech and Sanofi.
Michael Cho, JD
Chief Executive OfficerFormer CEO of Curi Bio. Experience building companies and partnerships around human tissue technologies.
Academic and employer affiliations describe individual experience. They do not imply institutional or employer endorsement, partnership with OncoVisio, or company ownership of affiliated research.
Let’s advance the understanding